Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance

Pfizer reported Q4 revenues of $17.76 billion, exceeding Wall Street projections7.

The company's COVID-19 portfolio outperformed expectations, with Paxlovid generating $727 million in sales, surpassing analyst forecasts of $630.7 million7.

Pfizer's COVID-19 vaccine brought in $3.4 billion, exceeding the $3 billion sales projection despite a $2 billion year-over-year drop7.

The company's cost-cutting initiatives are on track to deliver approximately $4.5 billion in net savings by the end of 20255.

Pfizer anticipates an additional $500 million in savings in 2025 from its ongoing cost realignment program1.

For 2025, Pfizer reaffirmed its revenue guidance of $61 billion to $64 billion and adjusted diluted earnings per share of $2.80 to $3.006.

The company expects a net unfavorable impact of approximately $1 billion on 2025 revenue due to the Inflation Reduction Act Part D Redesign changes1.

Pfizer's Q4 net income improved to $410 million ($0.07 per share) from a net loss of $3.37 billion ($-0.60 per share) in the previous year7.

The company's adjusted EPS for Q4 was $0.63, reflecting the impact of cost-cutting measures7.

Pfizer's long-term strategy includes growing its dividend, reinvesting in the business, and potentially making share repurchases after reducing its debt8.